In this review:
Hodgkin lymphoma
Aggressive lymphoma
Radiotherapy and early stage
Indolent lymphoma: R-CVP vs. R-CHOP vs. R-FM in advanced-stage FL initial treatment
PET: risk-adapted therapy in advanced stage DLBCL
CLL: PCI-32765 in poor-risk CLLT-cell lymphomas: brentuximab vedotin in relapsed/refractory
systemic ALCL
Download PDF